株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

がん免疫療法市場・臨床パイプライン分析

Cancer Immunotherapy Market & Clinical Pipeline Insight

発行 KuicK Research 商品コード 308563
出版日 ページ情報 英文 1990 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
がん免疫療法市場・臨床パイプライン分析 Cancer Immunotherapy Market & Clinical Pipeline Insight
出版日: 2014年07月22日 ページ情報: 英文 1990 Pages
概要

2013年において世界では600万人以上が癌で亡くなり、癌は世界のほとんど全ての経済諸国が直面する緊急の医療問題のひとつとなっています。がん免疫療法は、がん治療の分野において大きな可能性を持つ治療法のひとつです。

当レポートでは、世界のがん免疫療法市場と新薬の開発動向について調査し、がん免疫療法市場の概要、がん免疫療法市場の力学、がん免疫療法のパイプライン、ならびにがんモノクロナール抗体、がんワクチン、腫瘍溶解性ウィルス、がんサイトカイン療法、およびがん細胞療法の治験分析をフェーズ・国ごとに分析しており、主要医薬品事業者のプロファイルなどをまとめています。

第1章 イントロダクション:がん免疫療法

第2章 がん免疫療法のメカニズム

  • 遺伝子工学
  • ハイブリドーマ技術
  • モノクロナール抗体のヒト型化
  • 現代技術によるHAMA反応の克服

第3章 がん免疫療法の種類

  • モノクロナール抗体
  • チェックポイント阻害剤
  • ワクチン接種
  • 非特異性免疫療法

第4章 がん免疫療法が必要な理由

第5章 世界のがん免疫療法市場概要

第6章 がん免疫療法市場力学

  • 好ましい市場成長促進因子
  • 議論される主な課題
  • がん免疫療法の将来

第7章 がんモノクロナール抗体の臨床パイプライン:フェーズ・国別

  • 臨床パイプライン概要
  • 臨床パイプライン分析:研究から登録まで
  • 市販のがんモノクロナール抗体

第8章 がんワクチンの臨床パイプライン:フェーズ・国別

  • 臨床パイプライン概要
  • 臨床パイプライン分析:研究から登録まで
  • 市販のがんワクチン

第9章 腫瘍溶解性ウイルスの臨床パイプライン:フェーズ・国別

  • 臨床パイプライン概要
  • 臨床パイプライン分析:研究から登録まで

第10章 がんサイトカイン療法の治験分析:フェーズ・国別

  • 臨床パイプライン概要
  • 臨床パイプライン分析:研究から登録まで
  • 市販のがんサイトカイン療法薬

第11章 がん細胞療法の治験分析:フェーズ・国別

  • 臨床パイプライン概要
  • 臨床パイプライン分析:研究から登録まで
  • 市販のがん細胞治療薬

第12章 競合情勢:事業概要・製品パイプライン

  • Advaxis
  • Celldex Therapeutics
  • Dendreon Corporation
  • Galena Biopharma
  • ImmunoCellular Therapeutics
  • ImmunoGen
  • Inovio Pharmaceuticals
  • Merck
  • NeoStem Oncology
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novartis
  • Peregrine Pharmaceuticals
  • Roche
  • Seattle Genetics

図表

目次

With more than 6 million deaths worldwide in 2013, cancer has become one of the most pressing health problems faced by almost all the economies of the world. Inspite of the fact that there have been significant improvisation and advancements in surgery, radiation therapy, and chemotherapy over the years, there has hardly been any significant control of this disease by these treatments. There have been many developments in the recent past, in terms of introducing novel methods of treatment of cancer, which are likely to have a great potential. Cancer immunotherapy is one such development in the field of cancer treatment. This treatment option involves manipulating the human body's immune system in order to target the cancer.

The recent years have witnessed the emergence of cancer immunotherapy, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past 15-20 years, the researchers have increased their learning about the human body's immune system, which has led to the achievement of significant number of regulatory milestones during this period. Cancer immunotherapy has been made commercial and the market availability of the agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's immune system.

There has been some extensive research in the previous decade which has led to the development of vital novel therapies for diseases such as bladder cancer, renal cell carcinoma, colon cancer, and some leukemias. Additionally, these significant achievements in cancer immunotherapy have been popular on similar lines as improved techniques such as genetic engineering and monoclonal antibody generation. Thus, both these set of advancements have been working hand-in-hand to bring the cancer immunotherapy on the growth trajectory. The future is also likely to witness a continued close association between these two fields of advancements.

Cancer immunotherapy will continue to be overflowing with huge potential as a result of an increasing number of new discoveries and techniques. Inspite of advances being made in terms of understanding of the complexities of the human immune system, as compared to the state of immunology during Dr. Coley, there is still significant work which needs to be done. The complete detailed understanding is yet to be deciphered, which is one of the major reasons for cancer immunotherapy not being in widespread use.

“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:

  • Cancer Immunotherapy Market Overview
  • Cancer Immunotherapy Market Dynamics
  • Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
  • Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
  • Cancer Vaccine Clinical Pipeline by Phase & Country
  • Oncolytic Viruses Clinical Pipeline by Phase & Country
  • Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
  • Cancer Cell Therapy Clinical Trial Insight by Phase & Country
  • Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline

Table of Contents

1. Introduction to Cancer Immunotherapy

2. Mechanism of Cancer Immunotherapy

  • 2.1. Genetic engineering
  • 2.2. Hybridoma Technology
  • 2.3. Humanization of Monoclonal Antibodies
  • 2.4. Overcoming the HAMA Response via Modern Technology

3. Types of Cancer Immunotherapy

  • 3.1. Monoclonal Antibodies
  • 3.2. Checkpoint Inhibitors
  • 3.3. Vaccination
  • 3.4. Non Specific Immunotherapies

4. Why Need for Cancer Immunotherapy

5. Global Cancer Immunotherapy Market Overview

6. Cancer Immunotherapy Market Dynamics

  • 6.1. Favorable Market Drivers
  • 6.2. Key issues to be Discussed
  • 6.3. Future of Cancer Immunotherapy

7. Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country

  • 7.1. Clinical Pipeline Overview
  • 7.2. Clinical Pipeline Insight: Research till Registration
  • 7.3. Marketed Cancer Monoclonal Antibodies

8. Cancer Vaccine Clinical Pipeline by Phase & Country

  • 8.1. Clinical Pipeline Overview
  • 8.2. Clinical Pipeline Insight: Research till Registration
  • 8.3. Marketed Cancer Vaccines

9. Oncolytic Viruses Clinical Pipeline by Phase & Country

  • 9.1. Clinical Pipeline Overview
  • 9.2. Clinical Pipeline insight: Research till Registration

10. Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country

  • 10.1. Clinical Pipeline Overview
  • 10.2. Clinical Pipeline Insight: Research till Preregistration
  • 10.3. Marketed Cancer Cytokines Threapy

11. Cancer Cell Therapy Clinical Trial Insight by Phase & Country

  • 11.1. Clinical Pipeline Overview
  • 11.2. Clinical Pipeline Insight: Research till Preregistration
  • 11.3. Marketed Cancer Cell Therapy

12. Competitive Landscape: Business Overview & Product Pipeline

  • 12.1. Advaxis
  • 12.2. Celldex Therapeutics
  • 12.3. Dendreon Corporation
  • 12.4. Galena Biopharma
  • 12.5. ImmunoCellular Therapeutics
  • 12.6. ImmunoGen
  • 12.7. Inovio Pharmaceuticals
  • 12.8. Merck
  • 12.9. NeoStem Oncology
  • 12.10. NewLink Genetics
  • 12.11. Northwest Biotherapeutics
  • 12.12. Novartis
  • 12.13. Peregrine Pharmaceuticals
  • 12.14. Roche
  • 12.15. Seattle Genetics

List of Figures

  • Figure 1-1: Introduction to Cancer Therapies
  • Figure 1-2: Key Events in the History of Cancer Immunotherapy
  • Figure 2-1: Mechanism of Cancer Immunotherapy
  • Figure 3-1: Type of Cancer Immunotherapy
  • Figure 5-1: Cancer Immunotherapy Market Category
  • Figure 5-2: Cancer Immunotherapy Market (US$ Billion), 2014-2020
  • Figure 5-3: Cancer Immunotherapy Market by Region (%), 2014 & 2020
  • Figure 5-4: Regulatory Milestones for Cancer Immunotherapy
  • Figure 7-1: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2014
  • Figure 7-2: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2014
  • Figure 8-1: Cancer Vaccine Clinical Pipeline by Phase (%), 2014
  • Figure 8-2: Cancer Vaccine Clinical Pipeline by Phase (Number), 2014
  • Figure 9-1: Oncolytic Viruses Clinical Pipeline by Phase (%), 2014
  • Figure 9-2: Oncolytic Viruses Clinical Pipeline by Phase (Number), 2014
  • Figure 10-1: Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 10-2: Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 11-1: Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 11-2: Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 12-1: Advaxis Clinical Pipeline
  • Figure 12-2: Celldex Therapeutics Clinical Pipeline
  • Figure 12-3: Galena Biopharma Clinical Pipeline
  • Figure 12-4: ImmunoCellular Therapeutics Clinical Pipeline
  • Figure 12-5: ImmunoGen Clinical Pipeline
  • Figure 12-6: Inovio Pharmaceuticals Clinical Pipeline
  • Figure 12-7: NewLink Genetics Corporation Clinical Pipeline
  • Figure 12-8: Northwest Biotherapeutics Clinical Pipeline
  • Figure 12-9: Peregrine Pharmaceuticals Clinical Pipeline
  • Figure 12-10: Seattle Genetics Clinical Pipeline
Back to Top